Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 5/20 | 0.40 |
| ▸ | PARG | Q86W56 | 2/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482287 | 0.79 | LMNA (0.46) | HSD17B13LMNAPOLBCMA1 | |
| SCHEMBL30482276 | 0.78 | HSD17B13 (0.74) | HSD17B13 | |
| SCHEMBL25433299 | 0.78 | HSD17B13 (0.74) | HSD17B13 | |
| SCHEMBL30482353 | 0.78 | GNRHR (0.43) | HSD17B13LMNAPOLBCMA1PARG | |
| SCHEMBL31227182 | 0.78 | TSHR (0.41) | HSD17B13LMNAPOLBCMA1PARG | |
| SCHEMBL31501594 | 0.77 | HSD17B13 (0.46) | HSD17B13LMNAPOLB | |
| SCHEMBL30482368 | 0.71 | HSD17B13 (0.47) | HSD17B13LMNAPOLB | |
| SCHEMBL30482369 | 0.71 | HSD17B13 (0.47) | HSD17B13LMNAPOLB | |
| SCHEMBL3424865 | 0.70 | POLB (0.76) | LMNAPOLB | |
| SCHEMBL30482379 | 0.70 | HSD17B13 (0.39) | HSD17B13CMA1PARGGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4469451-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146897-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146897-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100993-A1 | 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | HSD17B13 3/4885LMNA 1642/4885POLB 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.